University of Colorado Cancer Center


 

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for AML"

418 views
June 7, 2023
0 Comments
Login to view comments. Click here to Login
Videos